The Manhattan Street Fund

Jupiter Endovascular, Inc., a medical technology startup based in Menlo Park, CA, has exited stealth mode with a $21 million new round of financing. The funding will support the company’s upcoming pivotal trial for Pulmonary Embolism and the development of additional Endoportal Control technology clinical applications.

Seven Starling, a Washington, DC-based virtual provider of women’s behavioral health services, raised $10.9M in funding. The company intends to use the funds to expand its reach and strengthen partnerships with over 1,000 OBGYNs and major health plans.

Outpace Bio, a Seattle, WA-based cell therapy company using AI-powered protein design to program immune cells for improved function inside patients battling solid tumors, raised $144m in financing.

Headway, the company building a new mental healthcare system, today announced a $100 million in funding round and its planned expansion to Medicare Advantage and Medicaid. These developments will further enable clinicians on the platform to scale their practices and provide affordable, effective mental health care to a broader and more diverse community of patients, including seniors, low-income Americans and individuals living with disabilities.

Thyme Care, a leading value-based cancer care enabler, has raised $95M in funding capital. The Company is focused on improving patient outcomes and reducing healthcare costs. The new funding will fuel Thyme Care’s expansion into new markets, deepen existing partnerships, and enhance its clinical value-based care model.

Element Biosciences, Inc., developer of pioneering technologies to empower science, announced over $277 million in investment to support its growing global customer base with disruptive DNA sequencing and multi-omics technologies for years to come.

Granza Bio, a San Francisco, CA-based therapeutic delivery platform developer, raised $7M+ in funding. The company intends to use the funds to expand operations and its development efforts.

VenoStent, Inc., a medical device company pioneering a new approach to improve dialysis patient outcomes, announced the successful completion of its funding round.

Coeptis Therapeutics (Nasdaq: COEP), a Wexford, PA-based biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, closed on $4.3m in financing. The company intends to use the funds for the repayment of outstanding obligations, working capital, and general corporate purposes.

InduPro, a Seattle, WA- and Cambridge, MA-based biotechnology company developing novel therapeutics for the treatment of cancer and autoimmune diseases, raised $85M in funding. The company intends to use the funds to support the advancement of the first expected clinical product candidate targeting cancer tissue based on the proximity of co-targeted pairs, from preclinical development to an expected IND filing in Q4 2025 for a Phase 1 clinical trial. It will also fuel a pipeline of novel bispecific antibodies and antibody-drug conjugates (ADCs) that utilize protein proximity to identify novel tumor-selective target pairings.

Sword Health, a true pioneer in the realm of AI-powered healthcare delivery, has just announced a significant $130M financing round. This brings Sword’s total funding to an impressive $340M and catapults the company’s valuation to a staggering $ 3 B, solidifying its position as a leader in the industry and attracting the attention of tech enthusiasts and healthcare professionals alike.

Matter Bio, a NYC-based biotech company dedicated to preserving genome integrity and extending healthy human lifespan, raised $7M in Seed funding. The company intends to use the funds to conduct further research into the information theory of aging at a genomic level, file an IND, and start a Phase 1/2a clinical trial in solid cancer

OncoveryCare, a Boston, MA-based company providing whole-person care to cancer survivors, raised $4.5M in Seed funding. The company intends to use the funds to continue growing its care delivery model and develop novel tools and approaches to scaling access to survivorship care more broadly.

SmarterDx — an AI startup that provides clinical review and quality audits for medical claims — closed a $50 million funding round, bringing its total funding to date to $71 million. The investment will drive product innovation that will create additional value for health systems, as well as support scale as the company expands.

Bluejay Therapeutics, a San Mateo, CA-based company which specializes in the development of novel therapeutics, raised $182M in funding. The company intends to use the funds to accelerate the clinical development of BJT-778, as the treatment for chronic hepatitis D (HDV) and support the progression of additional promising candidates in Bluejay’s robust pipeline for the treatment for chronic hepatitis B.

Latus Bio, a biotechnology company developing novel gene therapy candidates for disorders of the central nervous system (CNS), raised $54M in funding. The company intends to use the funds to accelerate the development of its candidates for CLN2 disease, with first-in-human dosing planned in late 2025.

PinkDx, Inc., a Daly City, CA-based company focused on positively impacting the health of women throughout their life journey, raised $40m in financing. The company will use the funds to test development, focusing initially on gynecological cancers.

Ilant Health, a pioneering leader in value-based obesity management and cardiometabolic health solutions, announced today the extension of its seed round of fundraising from $3 million to $5.5 million.

Grow Therapy, a mental health technology company, has raised $88 million in funding, which it plans to use to reach more patients.

Biolinq raked in $58 million in capital this week. The company is developing a wearable patch that uses electrochemical sensors to measure a person’s glucose levels from the intradermal space just beneath the surface of their skin.

Cancer drug developer Boundless Bio is a pioneer in therapies that target extrachromosomal DNA. The IPO cash will support its pipeline, including a lead program on track to report preliminary data later this year.

Capstan Therapeutics, a San Diego, CA-based biotechnology company dedicated to advancing in vivo reprogramming of cells through RNA delivery using targeted lipid nanoparticles (tLNP), raised 175M in funding. The company intends to use the funds to advance CPTX2309, its lead in vivo chimeric antigen receptor T cell (CAR-T) candidate, to early clinical proof-of-concept in autoimmune disorders, and to further develop Capstan’s tLNP pipeline.

HiLabs, a company that uses AI to manage dirty data, has raised $39 million in funding. The company plans to use the financing to scale its provider solution to more health insurers and grow its clinical solution, Garg stated.

Alumis has secured $259m in a funding round to progress the development of its clinical-stage pipeline of oral therapies to address immune dysfunction.

Cancer drug developer FogPharma has raised $145 million in fresh funding, The new financing will go toward an ongoing Phase 1/2 study in advanced solid tumors and support development of pipeline programs for other elusive cancer targets.

Elektra Health, a virtual provider for menopause care, has secured $3.3 million in financing. With the funding, the company is focused on two areas: partnering with more payers and expanding its footprint to provide clinical care to more patients.

Freenome, a San Francisco, CA-based biotechnology company developing blood tests for early cancer detection, raised $254M in funding. The company intends to use the funds to advance the pipeline of single-cancer and tailored multi-cancer early detection tests built on its multiomics platform.

Gilead-backed Kyverna Therapeutics on Wednesday said it will raise $319 million at a valuation of $898.1 million in an upsized U.S. initial public offering (IPO). The company said it plans to sell 14.5 million shares at $22 each, higher than its earlier price range of $20-$21 per share.

Alto Neuroscience will apply the IPO proceeds toward clinical tests of its psychiatric drugs in patients who exhibit certain biomarkers. The company's two most advanced programs are depression drugs in mid-stage development.

C16 Biosciences, a NYC-based maker of Palmless™, a platform for sustainable palm oil alternatives, raised $3.5M in Grant from Bill & Melinda Gates Foundation as well as a $1m investment from Elemental Excelerator. The company intends to use the funds to expand its platform by working with non-agriculturally derived feedstocks to produce food-grade oils and fats.